



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BOIGERGRAIN et al

Serial No.: 10/019,205

Filing Date: March 12, 2002

Group Art Unit: 1624

Examiner: Brenda Libby Coleman

FOR: ANTIPSYCHIOTIC CYCLIC N-ARALKYLAMINES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE

This is a response to the Office Action mailed February 19, 2004, setting a one-month period for response expiring March 19, 2004. Pursuant to the accompanying Petition for Extension of Time under 37 C.F.R. 1.136(a), the period for response is extended to June 19, 2004. This response is therefore timely filed.

Claims 1-35 are in the application. Restriction is required under 35 U.S.C. § 121 and 372 as follows:

Group I: Claims 1-35, drawn to compounds, compositions, process of preparing and method of use of the compounds where R₂ and R₃ form a 7-membered amine ring.

Group II: Claims 1, 2, 9-15, 22, and 29, drawn to compounds, compositions, process of preparing and method of use of the compounds where R₂ and R₃ form a 6-membered ring.

Group III: Claims 1, 2, 9-15, 22, and 29, drawn to compounds, compositions, process of preparing and method of use of the compounds where R₂ and R₃ form a 8-membered ring.

Group IV: Claims 1 and 9-14, drawn to compounds, compositions, process of preparing and method of use of the compounds where R₂ and R₃ form a 5-membered ring.

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Name

Geraldine S. Shi

Date

June 14, 2004

Group V: Claims 1 and 9-14, drawn to compounds, compositions, process of preparing and method of use of the compounds where R₂ and R₃ form a morpholinyl group.

Group VI: Claims 1 and 9-14, drawn to compounds, compositions, process of preparing and method of use of the compounds where R₂ and R₃ form a 4-phenyl-1,2,3,6-tetrahydropyridyl group.

Tentative election of a single species within the elected group is also required.

Applicants hereby elect Examiner's Group I, Claims 1-35, and within said group the species of Example 55, 1-[(Z)-3-(2-chloro-3'-methoxybiphenyl-4-yl)propen-2-yl]azepane, which species is read on by product Claims 1-8, process Claim 10, composition Claims 12 and 15-21, and method-of-use Claims 13, 14, and 22-35.

Respectfully submitted,



Paul E. Dupont
Reg. No. 27,438

Date: 6/14/04

Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Tele: (610) 889-6338
Fax: (610) 889-8799